On February 6, 2023 BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, reported that Keir Loiacono, Chief Executive Officer of BlueSphere Bio, will present a corporate overview at the 2023 BIO CEO & Investor Conference held in New York City, NY from February 6-9, 2023 (Press release, BlueSphere Bio, FEB 6, 2023, View Source [SID1234626862]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The in-person presentation will highlight the Company’s first and lead product candidate, BSB-1001, currently being developed for the treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and myeloid dysplastic syndrome (MDS) in conjunction with allogeneic hematopoietic stem cell transplantation (alloSCT). The Company anticipates filing its first investigational new drug application later this year.

Presentation details:
Date: Tuesday, February 7, 2023
Time: 10:30 a.m. ET
Location: Marriott Marquis Times Square

For more information about the BIO CEO & Investor Conference, please refer to the conference website at www.bio.org/events/bio-ceo-investor-conference.